Inhibikase Therapeutics Inc (NAS:IKT)

$ 1.1701 0.0098 (0.84%) Market Cap: 8.73 Mil Enterprise Value: 628,000.00 PE Ratio: 0 PB Ratio: 1.65 GF Score: 41/100

Q2 2024 Inhibikase Therapeutics Inc Earnings Call Transcript
Aug 15, 2024

$1.23 (-5.38%)

Earnings
Q1 2024 Inhibikase Therapeutics Inc Earnings Call Transcript
May 16, 2024

$1.76 (-11.56%)

Earnings
Q4 2023 Inhibikase Therapeutics Inc Earnings Call Transcript
Mar 28, 2024

$2.16 (-6.09%)

Earnings
Q2 2023 Inhibikase Therapeutics Inc Earnings Call Transcript
Aug 15, 2023

$2.34 (-6.02%)

Earnings
Inhibikase Therapeutics Inc at LD Micro Invitational Conference Transcript
Jun 06, 2023
Q1 2023 Inhibikase Therapeutics Inc Earnings Call Transcript
May 16, 2023

$3.91 (-1.33%)

Earnings
Q4 2022 Inhibikase Therapeutics Inc Earnings Call Transcript
Apr 03, 2023

$3.71 (-6.04%)

Earnings
Inhibikase Therapeutics Inc R&D Event Transcript
Mar 22, 2023
Q1 2022 Inhibikase Therapeutics Inc Earnings Call Transcript
May 17, 2022

$4.26 (+1.63%)

Earnings
Inhibikase Therapeutics Inc at B Riley Neuro & Ophthalmology Conference (Virtual) Transcript
Apr 28, 2022
Inhibikase Therapeutics Inc at LD Micro Microcap Invitational Conference (Virtual) Transcript
Jun 10, 2021
Inhibikase Therapeutics Inc at Sachs Associates Neuroscience Innovation Forum (Virtual) Transcript
Apr 28, 2021
Inhibikase Therapeutics Inc at Truist Securities Life Sciences Summit (April Series) Transcript
Apr 13, 2021
Inhibikase Therapeutics Inc at ASENT Neurotherapeutics Conference (Virtual) Transcript
Feb 25, 2021

Q1 2022 Inhibikase Therapeutics Inc Earnings Call Transcript

May 17, 2022 / 12:00PM GMT

Release Date Price: $4.26 (+1.63%)

Transcript 10-Q

Operator

Greetings. Welcome to Inhibikase Therapeutics' first-quarter 2022 financial results conference call. At this time, all participants are in listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions)

Please note this conference is being recorded.

I will now turn the conference over to Alex Lobo, Stern Investor Relations. Thank you. You may begin.

Alex Lobo

Stern IR - IR

Thank you, Sherry. Good morning and welcome to Inhibikase Therapeutics' first-quarter 2022 financial results conference call and audio webcast.

With me today is Dr. Milton Werner, Chief Executive Officer; and Joseph Frattaroli, Chief Financial Officer.

Yesterday, Inhibikase issued a press release announcing financial results for the first quarter ended March 31, 2022. We encourage everyone to read yesterday's press release, as well as Inhibikase's quarterly report on Form 10-Q for the first-quarter 2022, which is being filed with the SEC. The company's press release and quarterly report are also available on

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.